Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Topical tacrolimus for treatment-resistant cutaneous lupus erythematosus

A retrospective cohort study in 13 patients (19-76 years) with treatment-resistant cutaneous lupus erythematosus (CLE) evaluated the efficacy of tacrolimus 0.3% in clobetasol propionate 0.05% ointment (TCPO) for a mean duration of 20 months (range 1-72 months). Another five patients were treated with 0.1% tacrolimus ointment (TO) alone. Clinical response was graded as "poor", "slight", "good" or "excellent". "Good" or "excellent" responses were seen in 5 and 6 patients, respectively in the TCPO group. One patient showed "slight" improvement. In the TO group, two patients showed "slight" improvement and one patient "good" improvement. This small retrospective study in CLE patients showed that TCPO gave better results than TO, but further larger randomized ...